Connect Biopharma (CNTB) Competitors $0.82 -0.03 (-3.96%) Closing price 05/21/2025 03:59 PM EasternExtended Trading$0.80 -0.01 (-1.84%) As of 05/21/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTB vs. PRME, INMB, TLSA, MOLN, ELDN, OGI, INBX, PRQR, HURA, and DMACShould you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include Prime Medicine (PRME), INmune Bio (INMB), Tiziana Life Sciences (TLSA), Molecular Partners (MOLN), Eledon Pharmaceuticals (ELDN), Organigram (OGI), Inhibrx (INBX), ProQR Therapeutics (PRQR), TuHURA Biosciences (HURA), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. Connect Biopharma vs. Prime Medicine INmune Bio Tiziana Life Sciences Molecular Partners Eledon Pharmaceuticals Organigram Inhibrx ProQR Therapeutics TuHURA Biosciences DiaMedica Therapeutics Prime Medicine (NYSE:PRME) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability. Is PRME or CNTB more profitable? Connect Biopharma's return on equity of 0.00% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Prime MedicineN/A -107.87% -74.97% Connect Biopharma N/A N/A N/A Do insiders & institutionals have more ownership in PRME or CNTB? 70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 23.5% of Prime Medicine shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend PRME or CNTB? Prime Medicine currently has a consensus target price of $11.80, indicating a potential upside of 912.88%. Connect Biopharma has a consensus target price of $8.00, indicating a potential upside of 881.60%. Given Prime Medicine's higher probable upside, equities analysts plainly believe Prime Medicine is more favorable than Connect Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer PRME or CNTB? In the previous week, Prime Medicine had 17 more articles in the media than Connect Biopharma. MarketBeat recorded 20 mentions for Prime Medicine and 3 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 0.75 beat Prime Medicine's score of 0.02 indicating that Connect Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Connect Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor PRME or CNTB? Prime Medicine received 11 more outperform votes than Connect Biopharma when rated by MarketBeat users. However, 73.08% of users gave Connect Biopharma an outperform vote while only 65.22% of users gave Prime Medicine an outperform vote. CompanyUnderperformOutperformPrime MedicineOutperform Votes3065.22% Underperform Votes1634.78% Connect BiopharmaOutperform Votes1973.08% Underperform Votes726.92% Which has preferable earnings & valuation, PRME or CNTB? Connect Biopharma has higher revenue and earnings than Prime Medicine. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrime Medicine$3.85M39.77-$198.13M-$1.61-0.72Connect Biopharma$26.03M1.73-$59.50MN/AN/A Which has more risk and volatility, PRME or CNTB? Prime Medicine has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.3, meaning that its stock price is 130% less volatile than the S&P 500. SummaryPrime Medicine beats Connect Biopharma on 9 of the 16 factors compared between the two stocks. Get Connect Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTB vs. The Competition Export to ExcelMetricConnect BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.11M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E RatioN/A8.9226.7719.71Price / Sales1.73253.80393.17117.39Price / CashN/A65.8538.2534.62Price / Book0.456.466.794.50Net Income-$59.50M$143.98M$3.23B$248.18M7 Day Performance12.10%2.03%1.53%0.20%1 Month Performance16.46%4.11%10.06%12.37%1 Year Performance-52.06%-2.87%16.74%7.04% Connect Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTBConnect Biopharma3.2682 of 5 stars$0.82-4.0%$8.00+881.6%-54.0%$45.11M$26.03M0.00110Earnings ReportPRMEPrime Medicine3.7006 of 5 stars$1.34+3.1%$13.14+880.8%-85.5%$175.76M$3.85M-0.65234Trending NewsAnalyst ForecastAnalyst RevisionGap DownINMBINmune Bio1.9353 of 5 stars$7.64+9.6%$22.80+198.4%-29.4%$175.60M$14,000.00-3.5010Gap UpTLSATiziana Life Sciences1.0765 of 5 stars$1.50-4.5%N/A+73.2%$175.27MN/A0.008Gap UpMOLNMolecular Partners1.9444 of 5 stars$4.28+4.4%$12.00+180.4%+10.6%$172.81M$4.97M-1.99180Earnings ReportAnalyst RevisionELDNEledon Pharmaceuticals2.1569 of 5 stars$2.87-0.7%$12.50+335.5%+1.9%$171.86MN/A-1.4310News CoveragePositive NewsAnalyst RevisionGap UpOGIOrganigram0.2575 of 5 stars$1.28+8.5%N/A-30.2%$171.31M$166.12M-3.37860High Trading VolumeINBXInhibrx1.8939 of 5 stars$11.71+4.7%N/A-61.6%$169.51M$200,000.000.00166PRQRProQR Therapeutics3.1895 of 5 stars$1.59-1.2%$8.75+450.3%-9.5%$167.29M$18.91M-4.97180HURATuHURA BiosciencesN/A$3.82-4.3%$12.67+231.6%N/A$166.86MN/A0.00N/AEarnings ReportAnalyst RevisionDMACDiaMedica Therapeutics1.4867 of 5 stars$3.83+4.6%$8.00+108.9%+35.9%$164.14MN/A-6.8420Analyst RevisionGap Up Related Companies and Tools Related Companies PRME Competitors INMB Competitors TLSA Competitors MOLN Competitors ELDN Competitors OGI Competitors INBX Competitors PRQR Competitors HURA Competitors DMAC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTB) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
